GENENTECH, INC for GENENTECH INC
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act H.R. 2471 Consolidated Appropriations Act, FY2022 -Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills -Strategic National Stockpile (SNS) Funding and Oversight -Funding for FDA e-labeling rule implementation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to 340B program oversight -Support for increased investments to address antimicrobial resistance. -Deficit reduction, reconciliation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING New | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Copyright/Patent/Trademark CPT
S. 2891 - Restoring the America Invents Act -Intellectual property and process patent issues -Patent litigation reforms -PTAB and IPR processes -Section 101 Reform -Domestic and international compulsory licensing issues -March-in Rights
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
Health Issues HCR
H.R. 2163/S. 464 - Safe Step Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program H.R. 5376 - Build Back Better Act H.R. 3684- Infrastructure Investment and Jobs Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act S.2076/H.R. 3932 PASTEUR Act S. 3799- PREVENT Pandemics Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation -Patient access to Part B medicines during the COVID-19 public health emergency -Issues related to health equity, diversity, and inclusion in clinical trials -Issues related to advanced development and procurement of medical countermeasures (MCMs) -Issues related to patient assistance and access -Issues relating to privacy and securing the data of and personal information of consumers -Issues relating to medical research data -Issues relating to screening and diagnostics -Issues related to public health preparedness and response
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING New | — |
| DAN NEVES | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Medicare/Medicaid MMM
H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125 - the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -Issues related to CMMI
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Taxation/Internal Revenue Code TAX
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act H.R. 5376 - Build Back Better Act H.R.4521 - COMPETES Act of 2022 S.1260 - United States Innovation and Competition Act of 2021 -Issues related to R&D tax deductions and expense amortization -Issues related to international taxation, including foreign-derived intangible income and interest deductions -Issues related to supply chain incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Trade (domestic/foreign) TRD
H.R. 3788, the Protecting American Innovation Act H.R. 3811, the Trade Related Intellectual Property Protection Act H.R. 7185, the Federal Contracting for Peace and Security Act -Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver -Issues related to compulsory licensing of foriegn patents -Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
Medical/Disease Research/Clinical Labs MED
H.R. 2471 Consolidated Appropriations Act, FY2022 S.2076/H.R. 3932 PASTEUR Act H.R.____, the "Prescription Drug User Fee Amendments of 2022" S..____, the "Prescription Drug User Fee Amendments of 2022" H.R.6963 - Accelerated Approval Integrity Act of 2022 H.R.6996 - Accelerating Access for Patients Act of 2022 H.R. 2565 / S.2952 the FDA Modernization Act H.R. 6972 - Give Kids a Chance Act H.R. 1730 - STAT Act H.R. 7032 - Increasing Transparency in Generic Drug Applications Act H.R. 5030/S. 2706 - DIVERSE Trials Act H.R. 6584 - DEPICT Act -Issues related to public health protection including influenza development and preparedness -Issues related to antimicrobial and antiviral research and product development -Issues related to novel coronavirus and COVID-19 research and product development -Issues related to drug development including PDUFA and Cures 2.0
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| DAN NEVES | — |
| CATHERINE LYTTON PHILLIPS | — |
Pharmacy PHA
H.R. 2163/S. 464 - Safe Step Act H.R. 5376 - Build Back Better Act H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act -Drug pricing issues -Prescription Drug User Fee Act reauthorization -Issues related to prescription drug value -Issues related to the 340B Drug Discount Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| RAVI UPADHYAY | — |
Manufacturing MAN
S.3401 - Safe Drug Act H.R. 7121, Protecting our Pharmaceutical Supply Chain from China Act of 2022 S.3509 - Creating Efficiency in Foreign Facility Inspections Act -Issues related to pharmaceutical supply chains -Issues related to reporting on location of origin of pharmaceutical products -Issues related to drug shortages -Issues related to pharmaceutical manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN NEVES | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
Immigration IMM
-Issues relating to limits and restrictions on the immigration of high skilled workers -Issues relating to the immigration of medical researchers
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.